The concordance, sensitivity and specificity of EGFR mutation status by high-performance assays between plasma cfDNA and initial biopsy tisssue-derived tumor DNA in 29 NSCLC patients who were not performed re-biopsy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.